12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

LaViv regulatory update

Fibrocell submitted a response to a December 2009 complete response letter from FDA for a BLA for LaViv azficel-T to treat moderate...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >